MedTrace Logo

The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

NCT03154983 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2020-12-09

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Apatinib Mesylate Tablets combined with docetaxel and S-1 as the first-line treatment of metastatic gastric cancer.

Conditions

  • Metastatic Gastric Cancer

Interventions

DRUG

docetaxel

Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA\<1.25 40mg Po bid(twice a day), BSA \>=1.25-\<1.5 50mg Po bid, BSA \>=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.

Sponsors & Collaborators

  • Hubei Cancer Hospital

    collaborator OTHER

  • Huangshi Central Hospital

    collaborator OTHER

  • The Central Hospital of Huanggang

    collaborator OTHER

  • Xianning Central Hospital

    collaborator OTHER

  • Taihe Hospital

    collaborator OTHER

  • The first hospital of Zaoyang

    collaborator UNKNOWN

  • Hanchuan City people's Hospital

    collaborator UNKNOWN

  • Yangxin People's Hospital

    collaborator UNKNOWN

  • Tianmen People's Hospital

    collaborator UNKNOWN

  • Zhou Fuxiang

    lead OTHER

Principal Investigators

  • Fuxiang Zhou, M.D. · Wuhan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-20
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03154983 on ClinicalTrials.gov